Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy

It remains unclear why the clinically used anti-CTLA-4 antibodies, popularly called checkpoint inhibitors, have severe immunotherapy-related adverse effects (irAEs) and yet suboptimal cancer immunotherapeutic effects (CITE). Here we report that while irAE-prone Ipilimumab and TremeIgG1 rapidly direc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yan, Du, Xuexiang, Liu, Mingyue, Tang, Fei, Zhang, Peng, Ai, Chunxia, Fields, James K., Sundberg, Eric J., Latinovic, Olga S., Devenport, Martin, Zheng, Pan, Liu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796842/
https://www.ncbi.nlm.nih.gov/pubmed/31267017
http://dx.doi.org/10.1038/s41422-019-0184-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796842/
https://www.ncbi.nlm.nih.gov/pubmed/31267017
http://dx.doi.org/10.1038/s41422-019-0184-1

Ejemplares similares